BioPharmSignal logoBioPharmSignal

Biotech News

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

Y-mAbs (YMAB)Y-mAbsEarnings

Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network ® (NCCN ® ) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA ® ) Dosed first

Related news

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

View all latest news

Y-mAbs

Y-mAbs Therapeutics is an oncology and rare-disease company focused on antibody-based therapies. Its platform has been built around highly specific biologic treatments for difficult diseases.

Recent company news

YMABY-mAbs2025-09-16 12:41 EST

SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics

YMABY-mAbs2025-08-08 10:35 EST

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

YMABY-mAbs2025-08-07 11:30 EST

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

YMABY-mAbs2025-08-05 12:30 EST

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

YMABY-mAbs2025-05-28 10:35 EST

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States